What You Need to Know About the Newest Antidepressants
In addition to therapy, medication can be an invaluable treatment for clinical depression. It may alleviate symptoms and literally save lives. Which is why having an array of medications to choose from is vital. Recently, in the U.S., three antidepressants were approved by the Food and Drug Administration (FDA) to treat depression: vilazodone (Viibryd) in 2011; levomilnacipran (Fetzima) in 2013; and vortioxetine (Trintellix; formerly called Brintellix, but renamed to avoid confusion with the blood-thinning medication Brilinta) in 2013. In general, these medications are well-tolerated and effective. However, they’re n...
Source: Psych Central - May 21, 2018 Category: Psychiatry Authors: Margarita Tartakovsky, M.S. Tags: Depression Disorders General Medications Antidepressants Clinical Depression Fetzima Levomilnacipran Major Depression Major Depressive Disorder newest antidepressants Trintellix Viibryd Vilazodone vortioxetine Source Type: news

New research fails to support efficacy of desvenlafaxine for treating MDD in adolescents
(Mary Ann Liebert, Inc./Genetic Engineering News) New studies in children and adolescents with major depressive disorder (MDD) reported negative outcomes, failing to support the effectiveness of desvenlafaxine (Pristiq, Pfizer) compared to placebo. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 21, 2018 Category: International Medicine & Public Health Source Type: news

Mylan Launches Generic Pristiq(R) Tablets
HERTFORDSHIRE, England and PITTSBURGH, March 10, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, a generic version of Pfizer's ... Biopharmaceuticals, Generics, Product Launch Mylan, Desvenlafaxine, Pfizer, Pristiq (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 10, 2017 Category: Pharmaceuticals Source Type: news

Alembic Pharma's partner launches drug for depressive disorder
Alembic Pharma had received approval of its ANDA of desvenlafaxine succinate extended release tablets of strengths 50 mg and 100 mg in June 2015. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 3, 2017 Category: Pharmaceuticals Source Type: news

Khedezla (Desvenlafaxine Extended-release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 18, 2016 Category: Drugs & Pharmacology Source Type: news

Pristiq (Desvenlafaxine Extended-Release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 20, 2016 Category: Drugs & Pharmacology Source Type: news

Venlafaxine abuse
2.5 out of 5 stars Venlafaxine as the ‘baby ecstasy’? Literature overview and analysis of web-based misusers’ experiences. Francesconi G et al. Hum Psychopharmacol Clin Exp 2015 Jul;30:255-261.  Abstract In 2003, Sattar et al published a case report of venlafaxine abuse in a 38-year-old man. The patient had been prescribed 225-mg extended-release venlafaxine daily. He found that increasing his dose by 50% — to 337.5-mg per day — initially produced a “sudden, amphetamine-like ‘high'” that he did not re-experience even after increasing the dose to 450-mg. He subs...
Source: The Poison Review - July 30, 2015 Category: Toxicology Authors: Leon Tags: Medical abuse effexor overdose venlafaxine Source Type: news

Pfizer Trial of Antidepressant Fails to Meet Goal
Pfizer Inc. said that a clinical study of its antidepressant Pristiq in children failed to show that the treatment was more effective than a placebo. (Source: WSJ.com: Health)
Source: WSJ.com: Health - June 11, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news

Pfizer's Pristiq Phase IV trial shows low potential for sexual dysfunction in MDD patients
Pfizer has reported positive results from its Phase IV clinical trial of Pristiq (desvenlafaxine) in adult patients with major depressive disorder (MDD). (Source: Drug Development Technology)
Source: Drug Development Technology - October 31, 2014 Category: Pharmaceuticals Source Type: news

Pfizer's Phase IV trial of sexual dysfunction drug Pristiq meets primary end point
Pfizer has reported positive results from its Phase IV clinical trial of Pristiq (desvenlafaxine) to treat sexual dysfunction in adult patients with major depressive disorder (MDD). (Source: Drug Development Technology)
Source: Drug Development Technology - October 31, 2014 Category: Pharmaceuticals Source Type: news

desvenlafaxine (Pristiq, Khedezla)
Title: desvenlafaxine (Pristiq, Khedezla)Category: MedicationsCreated: 1/7/2009 12:00:00 AMLast Editorial Review: 8/6/2014 12:00:00 AM (Source: MedicineNet Depression General)
Source: MedicineNet Depression General - August 6, 2014 Category: Psychiatry Source Type: news

Meds Don't Help Anymore
Tortoiseshell on our forum asked the following question: I feel it is time for me to change meds or add something to the current meds. I am currently on Pristiq 100mg/day and Lamictal 200 mg/day. Increasing the dose didn't help, but worsened the side effects. These meds worked relatively well for me for 3 years until last September I had very emotionally difficult situation and got into destructive relationship. It threw me back again. Since then I haven't been able to enjoy myself and life despite of going to counseling weekly. Just not getting better. I am seeing my psychiatrist next week. She is very flexible ab...
Source: About.com Depression - April 22, 2014 Category: Psychiatry Source Type: news

Khedezla (Desvenlafaxine Extended-release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 22, 2013 Category: Drugs & Pharmacology Source Type: news

Meds Don't Help Anymore
Tortoiseshell on our forum asked the following question: I feel it is time for me to change meds or add something to the current meds. I am currently on Pristiq 100mg/day and Lamictal 200 mg/day. Increasing the dose didn't help, but worsened the side effects. These meds worked relatively well for me for 3 years until last September I had very emotionally difficult situation and got into destructive relationship. It threw me back again. Since then I haven't been able to enjoy myself and life despite of going to counseling weekly. Just not getting better. I am seeing my psychiatrist next week. She is very flexible ab...
Source: About.com Depression - May 30, 2013 Category: Psychiatry Source Type: news

Nonhormonal Option for Hot Flashes: Good NewsNonhormonal Option for Hot Flashes: Good News
JoAnn Manson discusses 3 studies on desvenlafaxine for menopausal vasomotor symptoms and concludes that the news is good. Medscape Ob/Gyn (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 6, 2013 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Commentary Source Type: news

Topline Phase 4 Results for SNRI ReleasedTopline Phase 4 Results for SNRI Released
Results from a large phase 4 study shows efficacy for desvenlafaxine 50 mg/day and 100 mg/day doses compared with placebo for the treatment of adult major depression. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 24, 2013 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Desvenlafaxine Safely Curbs Hot FlushesDesvenlafaxine Safely Curbs Hot Flushes
Desvenlafaxine (Pristiq, Pfizer) maintains its efficacy in reducing menopausal vasomotor symptoms and does so safely, according to two reports online December 24 in Menopause. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 4, 2013 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Desvenlafaxine safely curbs hot flushes
NEW YORK (Reuters Health) - Desvenlafaxine (Pristiq, Pfizer) maintains its efficacy in reducing menopausal vasomotor symptoms and does so safely, according to two reports online December 24 in Menopause. (Source: Modern Medicine)
Source: Modern Medicine - January 4, 2013 Category: Journals (General) Source Type: news